MacroGenics Inc (MGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
67
About the Report
About the Report
Summary
MacroGenics Inc (MacroGenics) is a clinical-stage biopharmaceutical company which focuses on the discovery, development and delivery of novel antibody-based therapeutics for the treatment of cancer, infectious diseases and autoimmune disorders. Its pipeline includes product candidates for the treatment of solid tumors, breast and gastroesophageal cancers type 1 diabetes, HIV, leukemia; and DART product candidates for the treatment of acute myeloid leukemia and myelodysplastic syndrome; colorectal cancer; and b-cell malignancies. The company's product candidates are based on three core proprietary technology platforms, namely, Cancer Stem Cell Platform, Dual-Affinity Re-Targeting (or DART) and TRIDENT Platform and Fc Optimization Platform. It also works in collaboration with major pharmaceutical and biotechnology companies to leverage its technology platforms and protein engineering capabilities to develop product candidates. MacroGenics is headquartered in Rockville, Maryland, the US.
MacroGenics Inc (MGNX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
MacroGenics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MacroGenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MacroGenics Inc, Medical Devices Deals, 2012 to YTD 2018 10
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MacroGenics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
Mirae Asset Global Investments Acquires 5% Stake in MacroGenics 12
Partnerships 13
MacroGenics Enters into Agreement with Merck 13
MacroGenics Enters into Co-Development Agreement with Takeda Pharma 14
Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 15
Licensing Agreements 17
Provention Bio Enters into Licensing Agreement with MacroGenics for PRV-3279 17
Roche Enters into Licensing Agreement with MacroGenics 18
Incyte Enters into Licensing Agreement with MacroGenics 19
MacroGenics Enters into Licensing Agreement with Synthon Biopharma 20
Janssen Biotech Enters into Licensing Agreement with MacroGenics for MGD015 21
MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 22
MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 24
Equity Offering 26
MacroGenics Raises USD110 Million in Public Offering of Shares 26
Macrogenics Plans to Raise up to USD75 Million in Public Offering of Shares 28
Macrogenics Raises USD23.7 Million in Private Placement of Shares 29
MacroGenics Raises USD150 Million in Public Offering of Shares 30
MacroGenics Raises USD75 Million in Private Placement of Common Stock 32
MacroGenics Completes Public Offering Of Shares For USD 82 Million 34
MacroGenics Completes IPO For USD 92 Million 36
Asset Transactions 38
Provention Bio Acquires PRV-031 from MacroGenics 38
MacroGenics Inc-Key Competitors 39
MacroGenics Inc-Key Employees 40
MacroGenics Inc-Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Nov 07, 2018: MacroGenics provides update on corporate progress and 3rd quarter 2018 financial results 42
Aug 07, 2018: MacroGenics provides update on corporate progress and 2nd quarter 2018 financial results 44
May 07, 2018: MacroGenics Provides Update on Corporate Progress and 1st Quarter 2018 Financial Results 46
Feb 27, 2018: MacroGenics Reports 2017 Financial Results 48
Nov 08, 2017: MacroGenics Provides Update on Corporate Progress and Third Quarter 2017 Financial Results 50
Aug 02, 2017: MacroGenics Provides Update on Corporate Progress and Second Quarter 2017 Financial Results 52
May 03, 2017: MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results 54
Feb 28, 2017: MacroGenics Provides Update on Corporate Progress and 2016 Financial Results 56
Corporate Communications 58
Nov 15, 2017: MacroGenics Names Dr. Jay Siegel to its Board of Directors 58
Jan 25, 2017: MacroGenics Announces Appointments to Board of Directors 59
Product News 60
11/10/2017: MacroGenics To Present Poster on MGD019 at 32nd Annual SITC Meeting 2017 60
09/05/2017: MacroGenics Provides Update on its DART candidate MGD013 61
Product Approvals 62
Sep 05, 2017: MacroGenics Advances Development of its DART candidate MGD014 62
Jan 05, 2017: MacroGenics' MGD006 Granted Orphan Drug Status for AML by FDA 63
Clinical Trials 64
Nov 10, 2017: MacroGenics Announces Poster Presentations on MGD013 at 32nd Annual SITC Meeting 2017 64
Sep 10, 2017: Phase 1 Data for Flotetuzumab, MacroGenics CD123 x CD3 DART Molecule, Presented at ESMO Congress 2017 65
Jul 17, 2017: Phase 1 Data for Flotetuzumab, MacroGenics CD123 x CD3 DART Molecule, Accepted for Oral Presentation at ESMO Congress 2017 66
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67
List of Figure
List of Figures
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MacroGenics Inc, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
MacroGenics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MacroGenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MacroGenics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
MacroGenics Inc, Medical Devices Deals, 2012 to YTD 2018 10
MacroGenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Mirae Asset Global Investments Acquires 5% Stake in MacroGenics 12
MacroGenics Enters into Agreement with Merck 13
MacroGenics Enters into Co-Development Agreement with Takeda Pharma 14
Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 15
Provention Bio Enters into Licensing Agreement with MacroGenics for PRV-3279 17
Roche Enters into Licensing Agreement with MacroGenics 18
Incyte Enters into Licensing Agreement with MacroGenics 19
MacroGenics Enters into Licensing Agreement with Synthon Biopharma 20
Janssen Biotech Enters into Licensing Agreement with MacroGenics for MGD015 21
MacroGenics Exercised Option For Licensing Agreement With Servier For DART Products 22
MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 24
MacroGenics Raises USD110 Million in Public Offering of Shares 26
Macrogenics Plans to Raise up to USD75 Million in Public Offering of Shares 28
Macrogenics Raises USD23.7 Million in Private Placement of Shares 29
MacroGenics Raises USD150 Million in Public Offering of Shares 30
MacroGenics Raises USD75 Million in Private Placement of Common Stock 32
MacroGenics Completes Public Offering Of Shares For USD 82 Million 34
MacroGenics Completes IPO For USD 92 Million 36
Provention Bio Acquires PRV-031 from MacroGenics 38
MacroGenics Inc, Key Competitors 39
MacroGenics Inc, Key Employees 40
MacroGenics Inc, Other Locations 41
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.